Anemia of chronic renal disease as well as cancer and chemotherapy‐induced anemia (CIA) are often associated with poor outcomes, and the use of erythropoietin stimulating agents (ESAs) for patients with chronic kidney disease (CKD) and anemia associated with cancer has been a common practice. This evidence concerns the gene EPO and anemia.